India approves first dengue vaccine QDENGA: who can take it, efficacy, safety
UPSC / SSC current affairs note
Why in news
India has approved its first dengue vaccine, QDENGA, developed by Takeda, marking a significant milestone in the country's fight against dengue. The approval comes as dengue continues to pose a major public health challenge during monsoon season. Doctors explain who can take it, how effective it is, and why mosquito precautions remain essential.
Background
Dengue is a mosquito-borne viral disease that causes severe illness and hospitalisations in India, especially during monsoons. Previously, no dengue vaccine was approved in India. QDENGA is the first vaccine approved in India for protection against all four dengue virus serotypes.
Key facts
QDENGA is India's first approved dengue vaccine, developed by Takeda.
It is approved for individuals aged 4 to 60 years.
The vaccine is administered in two doses, with the second dose given three months after the first.
It is designed to protect against all four dengue virus serotypes.
Clinical studies show QDENGA provides good protection against symptomatic dengue and significantly reduces risk of severe disease and hospitalisation.
The vaccine does not guarantee 100% protection; effectiveness may vary.
People should consult a healthcare provider to determine if the vaccine is appropriate for them.
Mosquito precautions remain essential even after vaccination.
Prelims pointers
- QDENGA: India's first dengue vaccine
- Developed by Takeda
- Approved for ages 4 to 60 years
- Two-dose schedule: second dose after 3 months
- Protects against all four dengue serotypes
Mains angles
- GS2 Health: Discuss the significance of India's first dengue vaccine in public health policy and disease burden reduction.
- GS3 Science and Technology: Evaluate the efficacy and limitations of QDENGA in controlling dengue outbreaks.
- GS2 Health: Critically examine the role of vaccination vs. vector control in managing mosquito-borne diseases.